An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient Program
About this study
The study is pilot, observational, retrospective, Italian multicenter study.
- Condition
- Diffuse Large B Cell Lymphoma (DLBCL)
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 6
- Minimum age: 18 years
- Study condition: Diffuse Large B Cell Lymphoma (DLBCL)
- Histologically confirmed diagnosis of R/R DLBCL.
- Patientswho received at least one dose of tafasitamab in association with lenalidomide under the NPP (D.M. 7 Sep 2017), between April 2022 and December 2022.
- Age ≥ 18 years at enrollment.
- Signature of written informed consent (if applicable).
Exclusion 1
- \) R/R DLBCL patients who received tafasitamab in association with lenalidomide in a clinical trial context.
Where
11 sites, 11 recruiting
IRCCS Azienda Ospedaliero - Universitaria di Bologna
Bologna, Bologna, Italy
AO Sant'Anna e San Sebastiano di Caserta
Caserta, Caserta, Italy
A.R.N.A.S. Garibaldi
Catania, Catania, Italy
Azienda Ospedaliera Universitaria Arcispedale S. Anna
Ferrara, Italy
Azienda Ospedaliero Universitaria Careggi
Florence, Italy
Irccs Ospedale San Raffaele
Milan, Italy
and 5 more sites on ClinicalTrials.gov
Contact
-
Pier Luigi Zinzani, MD
+39 0512144042 pierluigi.zinzani@unibo.it
-
Beatrice Casadei, MD
+39 0512143680 beatrice.casadei@aosp.bo.it
Potential match only. Final eligibility is determined by the study team.